GlassBury AI combines agentic patient matching with culturally sensitive community education to eliminate healthcare disparities. By pairing AI with expert-curated workshops, we build the trust necessary to connect underrepresented patients with life-changing clinical trials.
Tiny Bubbles, Big Breakthrough: How Exosomes Carry Alzheimer's Treatments Past the Blood–Brain Barrier
Your brain consumes roughly 20% of your body's energy, meaning it relies on a massive network of blood vessels. To protect your central nervous system from harmful chemical swings and infections, the cells lining these blood vessels fit together like microscopic puzzle pieces sealed with airtight biological glue. This tight network is the Blood–Brain Barrier.
The Role of AI in Therapeutic Drug Research and Development: Benefits and Challenges
Artificial intelligence (AI) has emerged as a transformative technology across various sectors, and its potential impact on therapeutic drug research and development is significant. By leveraging AI algorithms and machine learning, researchers can potentially accelerate the drug discovery process, identify promising drug candidates, and optimize treatment strategies. However, the integration of AI
The Role of Government in Fostering a Thriving Entrepreneurial Environment for Drug Research and Development
The United States government plays a pivotal role in shaping the landscape for drug research and development (R&D), fostering an environment where entrepreneurial endeavors can flourish. This blog post delves into the multifaceted ways in which the government contributes to this ecosystem, drawing insights from authoritative sources and expert opinions.
AI Revolution: Accelerating Drug Discovery for Alzheimer's and Neurological Disorders
The discovery of effective therapeutics against Alzheimer’s disease (AD) and other complex neurological disorders remains one of the most significant challenges in modern medicine. These diseases represent a multifactorial crisis with limited therapeutic options available for management and notoriously limited clinical efficacy.
Decoding the Latest Alzheimer's Setback: Why J&J’s "Failed" Drug Trial is Actually a Hidden Victory for Brain Science
When we think about the fight against Alzheimer’s disease, we often picture a coordinated, unstoppable march toward a cure led by massive organizations like the National Institute on Aging and the Alzheimer's Association. However, the reality of medical research is rarely a straight line. It is a grueling, complex process filled with trial, error, and unexpected pivots.
The Titans of Memory: Inside the Top 7 Organizations Fighting Alzheimer’s Disease
Alzheimer’s research in the United States is a massive, multi-billion-dollar ecosystem led by a mix of federal agencies, non-profit foundations, and elite academic medical centers.
GlassBury Insight: The 7 Alzheimer’s Breakthroughs of 2026
Welcome to the GlassBury Insight Series. As we navigate the midpoint of 2026, the landscape of neurodegenerative research has shifted from cautious optimism to a full-throttle revolution. The "inevitability" of cognitive decline is being dismantled by a new guard of precision diagnostics and bio-digital interventions.